Metsera Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Public

  • Employees
  • 74

Employees

  • Stock Symbol
  • MTSR

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $25.10
  • (As of Friday Closing)

Metsera General Information

Description

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Contact Information

Website
www.metsera.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3 World Trade Center
  • 175 Greenwich Street
  • New York, NY 10007
  • United States
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • 3 World Trade Center
  • 175 Greenwich Street
  • New York, NY 10007
  • United States

Metsera Timeline

202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Metsera Stock Performance

As of 14-Mar-2025, Metsera’s stock price is $25.10. Its current market cap is $2.66B with 105M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.10 $24.26 $23.08 - $32.81 $2.66B 105M 707K -$4.17

Metsera Financials Summary

As of 30-Sep-2024, Metsera has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
Revenue 0 0
EBITDA (173,040) (47,961)
Net Income (168,127) (46,048)
Total Assets 287,270 168,841 14,980
Total Debt 6,031 0 15,180
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Metsera Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Metsera‘s full profile, request access.

Request a free trial

Metsera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated
Drug Discovery
New York, NY
74 As of 2024

Cambridge, MA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Metsera Competitors (74)

One of Metsera’s 74 competitors is Aura Biosciences, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA
Kriya Venture Capital-Backed Palo Alto, CA
Kymera Therapeutics Formerly VC-backed Watertown, MA
Batavia Biosciences Corporate Backed or Acquired Leiden, Netherlands
Maze Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 74 competitors. Get the full list »

Metsera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metsera Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Metsera‘s full profile, request access.

Request a free trial

Metsera Acquisitions (1)

Metsera’s most recent deal was a Merger/Acquisition with Zihipp. The deal was made on 18-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zihipp 18-Apr-2024 Merger/Acquisition Drug Discovery
To view Metsera’s complete acquisitions history, request access »

Metsera Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Zihipp Bristol, United Kingdom 2012

Metsera FAQs

  • When was Metsera founded?

    Metsera was founded in 2022.

  • Where is Metsera headquartered?

    Metsera is headquartered in New York, NY.

  • What is the size of Metsera?

    Metsera has 74 total employees.

  • What industry is Metsera in?

    Metsera’s primary industry is Drug Discovery.

  • Is Metsera a private or public company?

    Metsera is a Public company.

  • What is Metsera’s stock symbol?

    The ticker symbol for Metsera is MTSR.

  • What is the current stock price of Metsera?

    As of 14-Mar-2025 the stock price of Metsera is $25.10.

  • What is the current market cap of Metsera?

    The current market capitalization of Metsera is $2.66B.

  • Who are Metsera’s competitors?

    Aura Biosciences, Kriya, Kymera Therapeutics, Batavia Biosciences, and Maze Therapeutics are some of the 74 competitors of Metsera.

  • What is Metsera’s annual earnings per share (EPS)?

    Metsera’s EPS for 12 months was -$4.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »